29 citations
,
September 2023 in “Journal of Clinical Medicine” Semaglutide helps obese PCOS patients lose weight and improve health.
4 citations
,
March 2025 in “Journal of Cosmetic Dermatology” Semaglutide may cause hair loss, but more research is needed to confirm this.
1 citations
,
August 2025 GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
July 2026 in “Preprints.org” Tirzepatide users experience more hair loss than semaglutide users.
March 2026 in “Journal of Pharmaceutical Research” Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.
January 2026 in “Quality in Sport” Semaglutide may help some skin disorders but can also cause skin issues.
A rash from semaglutide may be due to propylene glycol, not the drug itself.
December 2025 in “BJPsych Open” Semaglutide may worsen eating disorders in vulnerable individuals.
September 2024 in “Journal of the American Academy of Dermatology” Semaglutide does not significantly increase the risk of hair loss.
August 2026 in “Revista Ibero-Americana de Humanidades, Ciências e Educação” Rapid weight loss from weight-loss drugs, not the drugs themselves, mainly causes hair loss.
April 2026 in “Open MIND” GLP-1 medications can cause skin and muscle issues, but treatments like ultrasound and PRP can help.
59 citations
,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
25 citations
,
September 2024 in “Cardiovascular Drugs and Therapy” GLP1-RAs may have higher reports of suicidal events and hair loss compared to other diabetes drugs.
1 citations
,
September 2025 in “Medicina Moderna - Modern Medicine” Combining lifestyle changes with personalized medication is crucial for better managing obesity in PCOS.
July 2026 in “Journal of Investigative Dermatology” GLP-1 therapies can cause hair loss, but hair often regrows after stopping or reducing the drug.
July 2026 in “Journal of the American Academy of Dermatology” GLP-1 and GLP-1/GIP agonists may increase the risk of hair loss.
June 2026 in “Skin Appendage Disorders” GLP-1 receptor agonists may increase the risk of hair loss, especially non-scarring types, due to weight loss-related nutrient deficiencies.
GLP-1 receptor agonists increase the risk of hair loss, mainly due to weight loss-related nutrient deficiency.
GLP-1 receptor agonists increase the risk of hair loss, mainly due to nutrient deficiency from weight loss.
June 2026 in “Dermatology and Therapy” GLP-1RAs, like semaglutide and tirzepatide, may cause hair loss, so patients should be informed and monitored.
May 2026 in “Pharmaceuticals” Incretin-based drugs for obesity often cause gastrointestinal issues, with tirzepatide having the most reports.
April 2026 in “Science Progress” GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
October 2025 in “International Journal of Dermatology” GLP-1 receptor agonists may cause hair loss, but regrowth is rare.
October 2025 in “JEADV Clinical Practice” GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.
October 2025 in “Brazilian Journal of Hair Health” Hair loss from weight-loss treatments is usually temporary and reversible.
September 2025 in “Cureus” GLP-1 receptor agonists may cause hair loss, but more research is needed.
February 2025 in “medRxiv (Cold Spring Harbor Laboratory)” GLP-1 agonists may increase the risk of hair loss.
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Newer GLP-1 drugs like semaglutide may cause hair loss.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
May 2024 in “Psychiatric News” Weight-loss drugs are not linked to suicidal thoughts.